Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.
-SEC Filing
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50...
Benchmark analyst Robert Wasserman upgrades Nephros (NASDAQ:NEPH) from Hold to Speculative Buy and announces $5 price target.
Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.060) per share which missed the analyst consensus estimate of $(0.030) b...
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...
